These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2549450)

  • 1. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.
    Weiner HL; Dau PC; Khatri BO; Petajan JH; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav EJ
    Neurology; 1989 Sep; 39(9):1143-9. PubMed ID: 2549450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis.
    Weiner HL; Dau PC; Khatri BO; Petajan J; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav J
    Prog Clin Biol Res; 1990; 337():283. PubMed ID: 2162062
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.
    Gordon PA; Carroll DJ; Etches WS; Jeffrey V; Marsh L; Morrice BL; Olmstead D; Warren KG
    Can J Neurol Sci; 1985 Feb; 12(1):39-44. PubMed ID: 3884114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
    Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study.
    Meca-Lallana JE; Hernández-Clares R; León-Hernández A; Genovés Aleixandre A; Cacho Pérez M; Martín-Fernández JJ
    Clin Ther; 2013 Apr; 35(4):474-85. PubMed ID: 23541130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.
    Hahn AF; Bolton CF; Pillay N; Chalk C; Benstead T; Bril V; Shumak K; Vandervoort MK; Feasby TE
    Brain; 1996 Aug; 119 ( Pt 4)():1055-66. PubMed ID: 8813270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.
    Brochet B; Deloire M; Germain C; Ouallet JC; Wittkop L; Dulau C; Perez P; Thevenot F; De Sèze J; Zéphir H; Vermersch P; Pittion S; Debouverie M; Laplaud DA; Clavelou P; Ruet A
    J Clin Apher; 2020 Aug; 35(4):281-289. PubMed ID: 32369661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exchange in chronic progressive multiple sclerosis: a long-term study.
    Khatri BO; McQuillen MP; Hoffmann RG; Harrington GJ; Schmoll D
    Neurology; 1991 Mar; 41(3):409-14. PubMed ID: 2006010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma exchange (PE) and lymphocytapheresis (LCA) in multiple sclerosis (MS).
    Höcker P; Stellamor V; Summer K; Mann M
    Int J Artif Organs; 1984 Jan; 7(1):39-42. PubMed ID: 6698632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
    Llufriu S; Castillo J; Blanco Y; Ramió-Torrentà L; Río J; Vallès M; Lozano M; Castellà MD; Calabia J; Horga A; Graus F; Montalban X; Saiz A
    Neurology; 2009 Sep; 73(12):949-53. PubMed ID: 19770470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial.
    Simsarian JP; Saunders C; Smith DM
    Drug Des Devel Ther; 2011; 5():381-9. PubMed ID: 21792296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.
    Sørensen PS; Wanscher B; Szpirt W; Jensen CV; Ravnborg M; Christiansen P; Schreiber K; Nordenbo A
    Neurology; 1996 Jun; 46(6):1620-5. PubMed ID: 8649560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.